IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v21y2023i5d10.1007_s40258-023-00815-7.html
   My bibliography  Save this article

10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?

Author

Listed:
  • Melanie Büssgen

    (University of Hamburg)

  • Tom Stargardt

    (University of Hamburg)

Abstract

Objectives The German Pharmaceutical Market Restructuring Act (AMNOG, 2011) is a two-stage process to regulate the price of new pharmaceuticals in which price negotiations are conducted based on evidence-based medical benefit assessments using data from prior clinical trials. Although the act does not explicitly set a willingness-to-pay (WTP) threshold, the process itself implicitly establishes a WTP for health improvement. We evaluated the implicit WTP for prescription pharmaceuticals post-AMNOG in the German healthcare system from the decision-maker/payer perspective. Methods We extracted data on patient-group-specific annual treatment costs and endpoints from 2011 to 2021 from the dossiers assessed by the German Federal Joint Committee (FJC; Gemeinsamer Bundesausschuss). Using incremental cost-effectiveness ratios (ICERs), we calculated a WTP for the indications (I) diabetes, (II) cardiovascular disease, and (III) psoriasis weighted according to patient group size, first from the perspective of the decision-maker (approach A), and second from the perspective of the industry (approach B). To put clinical outcome measures into relation to one another, minimum clinically important differences (MCIDs) were derived from the literature and compared. Results The annual treatment costs of newly authorized drugs were substantially higher (both pre- and post-negotiation) than that of their comparators (e.g., psoriasis, pre-negotiation: €20,601.59, post-negotiation: €16,763.57; comparators: €5178.00). However, although newly launched drugs were more expensive than their comparators, they brought greater medical benefits and were more aligned with value (r = 0.59, P

Suggested Citation

  • Melanie Büssgen & Tom Stargardt, 2023. "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?," Applied Health Economics and Health Policy, Springer, vol. 21(5), pages 751-759, September.
  • Handle: RePEc:spr:aphecp:v:21:y:2023:i:5:d:10.1007_s40258-023-00815-7
    DOI: 10.1007/s40258-023-00815-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40258-023-00815-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40258-023-00815-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Valérie Paris & Annalisa Belloni, 2013. "Value in Pharmaceutical Pricing," OECD Health Working Papers 63, OECD Publishing.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    2. Sabine Vogler & Valérie Paris & Alessandra Ferrario & Veronika J. Wirtz & Kees Joncheere & Peter Schneider & Hanne Bak Pedersen & Guillaume Dedet & Zaheer-Ud-Din Babar, 2017. "How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 307-321, June.
    3. William C. N. Dunlop & C. Daniel Mullins & Olaf Pirk & Ron Goeree & Maarten J. Postma & Ashley Enstone & Louise Heron, 2016. "BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles," PharmacoEconomics, Springer, vol. 34(10), pages 1051-1065, October.
    4. Sun-Hong Kwon & Hea-Sun Park & Young-Jin Na & Chul Park & Ju-Young Shin & Hye-Lin Kim, 2021. "Price Reduction of Anticancer Drugs from 2007 to 2019 in South Korea: The Impact of Pharmaceutical Cost-Containment Policies," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 439-450, May.
    5. Rotar, Alexandru M. & Preda, Alin & Löblová, Olga & Benkovic, Vanesa & Zawodnik, Szymon & Gulacsi, Laszlo & Niewada, Maciej & Boncz, Imre & Petrova, Guenka & Dimitrova, Maria & Klazinga, Niek, 2018. "Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries," Health Policy, Elsevier, vol. 122(3), pages 230-236.
    6. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    7. Claude Montmarquette & Stéphanie Boulenger & Joanne Castonguay, 2014. "Les risques liés à la création de PHARMA-QUEBEC," CIRANO Project Reports 2014rp-05, CIRANO.
    8. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    9. Fernando Antoñanzas & Robert Terkola & Maarten Postma, 2016. "The Value of Medicines: A Crucial but Vague Concept," PharmacoEconomics, Springer, vol. 34(12), pages 1227-1239, December.
    10. Afschin Gandjour, 2016. "Limiting Free Pricing of New Innovative Drugs After Launch: A Necessity for Payers?," Applied Health Economics and Health Policy, Springer, vol. 14(5), pages 507-509, October.
    11. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
    12. Salas-Vega, Sebastian & Bertling, Annika & Mossialos, Elias, 2016. "A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK," Health Policy, Elsevier, vol. 120(10), pages 1104-1114.
    13. Melanie Büssgen & Tom Stargardt, 2023. "Does health technology assessment compromise access to pharmaceuticals?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(3), pages 437-451, April.
    14. Anna Hobbins & Luke Barry & Dan Kelleher & Koonal Shah & Nancy Devlin & Juan Manuel Ramos Goni & Ciaran O’Neill, 2018. "Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L," PharmacoEconomics, Springer, vol. 36(11), pages 1345-1353, November.
    15. David Epstein & Leticia García-Mochón & Stephen Kaptoge & Simon G. Thompson, 2016. "Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1041-1053, November.
    16. Dominik J. Wettstein & Stefan Boes, 2020. "The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: evidence from an online experiment," Health Economics Review, Springer, vol. 10(1), pages 1-15, December.
    17. Jorge Mestre-Ferrandiz & Néboa Zozaya & Bleric Alcalá & Álvaro Hidalgo-Vega, 2018. "Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?," PharmacoEconomics, Springer, vol. 36(12), pages 1407-1420, December.
    18. A. Carletto & A. Cicchetti & S. Coretti & V. Moramarco & M. Ruggeri, 2019. "Money back guarantee? A cost–benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals," Eurasian Business Review, Springer;Eurasia Business and Economics Society, vol. 9(1), pages 89-101, March.
    19. Afschin Gandjour, 2023. "A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany," Applied Health Economics and Health Policy, Springer, vol. 21(4), pages 627-635, July.
    20. García-Collado, Carlos Gustavo & Martínez-de-la-Plata, Juan Enrique & Montoro, María del Mar Maldonado & Morales, Alberto Jiménez & Hernández, Miguel Ángel Calleja & Martínez, Fernando Martínez, 2021. "Impact of a risk-sharing agreement in rheumatoid arthritis in Spain," Health Policy, Elsevier, vol. 125(3), pages 335-340.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:21:y:2023:i:5:d:10.1007_s40258-023-00815-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.